No profile data available.
ANI Pharmaceuticals, Inc. (ANIP) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Baudette, United States, with about 970 full-time employees.
It reported revenue of $883.37 million for fiscal year 2025, up 43.8% from fiscal year 2024, and net income of $70.22 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $266.04 million, up 25.9% from a year before. Its largest business segment, Rare Disease and Brands, brought in 55% of segment revenue in fiscal year 2025; United States was the largest region with 96%. Its market capitalization was $1.70 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
ANI Pharmaceuticals reported $883.37 million in revenue for fiscal year 2025, up 43.8% from $614.38 million in fiscal year 2024. In Q2 2026 revenue was $266.04 million.
Rare Disease and Brands, with $483.93 million or 55% of segment revenue in fiscal year 2025. Next: Generics and Other (45%).
United States: 96% of revenue by region in fiscal year 2025, followed by International (4%).
$1.70 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Perrigo Company plc (PRGO), Intellia Therapeutics, Inc. (NTLA), Xencor, Inc. (XNCR), Ocular Therapeutix, Inc. (OCUL).